Business Context and Reporting Period
This Form 8-K was filed by Sight Sciences, Inc. on November 9, 2023. The company, an emerging growth company incorporated in Delaware, operates in the medical device sector focusing on Micro-Invasive Glaucoma Surgery (MIGS). The report details significant regulatory developments regarding Medicare coverage and their immediate impact on the company's credit facilities.
Key Financial Metrics and Liquidity
The filing does not provide specific revenue, profit, or cash flow figures for the current period. However, it discloses the following financial obligations and historical context:
- Debt: The company holds a $35.0 million senior secured term loan under an agreement with MidCap Financial Services.
- Revenue Exposure: The five Medicare Administrative Contractors (MACs) involved in the recent coverage determinations accounted for approximately 63% of the company's Surgical Glaucoma revenue in 2022.
- Liquidity Strategy: Management is assessing strategies to preserve liquidity, including potential renegotiation or refinancing of indebtedness and further reduction of operating expenses.
Material Changes and Events
On November 9, 2023, four MACs (Palmetto GBA, Celerian Group Company, National Government Services, and Noridian Healthcare Solutions) published Local Coverage Determinations (LCDs) effective December 24, 2023. These determinations classify certain procedures, including canaloplasty in combination with trabeculotomy ab interno (associated with the company's OMNI Surgical System), as investigational for patients over 18. A fifth MAC, WPS Government Health Administrators, issued a similar LCD on October 26, 2023.
These regulatory actions constitute a "Reimbursement Trigger Event" under the company's credit agreement. Consequently, monthly principal payments on the $35.0 million term loan are expected to commence in January 2024. The company warns that if the LCDs take effect as planned, it may be unable to comply with revenue covenants in 2024, potentially triggering an event of default and allowing the lender to accelerate loan repayment.
Outlook, Management Commentary, and Risks
Management strongly disagrees with the characterization of OMNI-associated procedures as investigational. The company intends to pursue all remediation possibilities, including engaging with MACs, the Centers for Medicare and Medicaid Services, and clinical societies to delay the effective date of the LCDs or reinstate coverage. If the LCDs are implemented in their current form, the company plans to promptly initiate an LCD reconsideration request process.
Key risks identified include the potential loss of coverage for a significant portion of revenue, the commencement of mandatory debt principal payments, and the risk of an event of default under the credit agreement if revenue covenants are breached.
Investor Verification Checklist
- Verify the status of the LCD reconsideration requests and any potential delays to the December 24, 2023 effective date.
- Monitor the company's ability to meet the minimum revenue covenants under the MidCap Agreement in 2024.
- Assess the progress of any refinancing or debt renegotiation efforts to avoid an event of default.
- Review the specific coverage limitations for goniotomy procedures, which remain covered but with restrictions, and their impact on the SION Surgical Instrument technology.